12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lenvatinib: Phase II data

Data from 32 patients with recurrent GBM who progressed on Avastin bevacizumab treatment in a single-arm Phase II trial showed that once-daily 24 mg lenvatinib produced no observed objective responses. The 6-month PFS rate was 8.3% and median PFS was 1.9 months. Eisai said the historical 6-month PFS rate is 2% for recurrent GBM...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >